SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,589,443 with 63,351,197,653 in circulation. The last known price of XRP is 1.24455819 USD and is down -0.63 over the last 24 hours. It is currently trading on 1893 active market(s) with $917,900,293.08 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff linked by traders to the Binance hack, while Ripples Swell announcements have drawn disappointment over the tokens muted response. The main debate is whether Ripples partnerships, bank charter and RLUSD growth will create demand for XRP, or primarily benefit Ripple and its stablecoin instead.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the midterm elections and Trumps political fortunes, with traders debating how the outcome could affect DJT and broader markets; speculation over Iran-war escalation and oil prices adds to the uncertainty. Sentiment is mostly bearish, with posts citing DJTs sharp decline and weak fundamentals, though some traders anticipate a rebound.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical 

AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.

Bet on 5 Top-Ranked Stocks With Rising P/E 

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. 

Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

FDA Milestones Fueling Expansion

The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH

AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead

Equity

AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.

Biodefense Spotlight Sends Microcap Soaring

As global health agencies monitor emerging infectious disease threats, interest can return quickly to legacy therapeutic platforms with broad antiviral potential. In biotech, especially among smaller names, previously published research can suddenly become highly relevant when the right real-world catalyst emerges. Shares of AIM ImmunoTech Inc. (NYSE American: AIM) are ripping higher in Tuesday trading, climbing after the company highlighted previously published pre-clinical data supporting the potential use of its lead drug candidate, Ampligen, as a prophylactic or early-intervention ...

Why Did AIM Stock Plummet 35% Today?

AIM ImmunoTech announced an agreement with certain accredited investors to exercise outstanding warrants for $0.48 per share to raise $4.2 million in gross proceeds.

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

Why Did AIM Stock Jump 60% Today?

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

This account has been verified as an official AIM representative.

Verified Account

AIM_ImmunoTech

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

AIM ImmunoTech Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer.</li><li>The company said it is continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint.</li><li>AIM ImmunoTech said the planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study.</li></ul><p>Shares of AIM ImmunoTech Inc. (AIM) soared&nbsp;more than 200% in Monday morning’s trade after the company announced that its pancreatic cancer trial hit a key enrollment milestone ahead of schedule.</p><p>AIM ImmunoTech announced final patient enrollment in its Phase 2 study of Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer following FOLFIRINOX treatment.</p><p><a href="https://stocktwits.com/symbol/AIM">AIM ImmunoTech shares</a> were up more than 130% in Monday morning’s trade after paring some of the gains.</p><h2 class="st-heading-2">AIM CEO Says Ampligen Dosing On Track For Completion</h2><p>AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen, which should allow the company to evaluate the study's critical primary endpoint of Clinical Benefit Rate (CBR) in December 2026.</p><p>CBR measures the percentage of patients who achieve stable disease, a partial response or a complete response six months after starting the combination therapy.</p><p>“Together with our ongoing Phase 3 planning efforts, orphan drug designations in the United States and Europe, expanding global intellectual property portfolio, and growing body of positive clinical data, we believe Ampligen is advancing toward a significant value-inflection period for AIM,” Equels said.</p><h2 class="st-heading-2">AIM Advances Toward Phase 3 Development</h2><p>The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer.</p><p>The company said it is continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint. AIM added that the planned Phase 3 program is supported by previously published data from a Dutch government-approved Named Patient Program, as well as encouraging results from the ongoing DURIPANC study.</p><p>According to the company, more than 100 pancreatic cancer patients have been treated with Ampligen across these programs, helping the company acquire clinical experience to support the therapy's further development.</p><h2 class="st-heading-2">AIM’s Ampligen Ebola Presentation Due This Week</h2><p>AIM ImmunoTech announced last week that it plans to release an on-demand presentation highlighting previously published preclinical data supporting the potential use of Ampligen as both a preventive and early-stage antiviral treatment for Ebola virus disease.</p><p>The announcement comes amid rising concern over a Bundibugyo-strain Ebola outbreak in Central and East Africa, a variant that currently has no approved treatment or vaccine.</p><p>The company said research conducted at USAMRIID's Biosafety Level 4 laboratories demonstrated Ampligen's potential to address this unmet medical need.</p><h2 class="st-heading-2">How Did Retail Investors React To AIM Stock?</h2><p>Retail sentiment on Stocktwits around AIM ImmunoTech trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.</p><p><a href="https://stocktwits.com/symbol/AIM">AIM stock</a> is down 14% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is down 2%. The Vanguard Extended Market Index Fund ETF (VXF) is up 29% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smci-stock-price-target-hike-agentic-ai-nvidia-jensen-huang-computex/cZ0gthCReHY"><strong>SMCI Stock Gets Target Boost As Mizuho Cites Agentic AI Demand — Jensen Huang Says 'One Prompt Can Launch A Thousand-Step Journey'</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shares of REalloys Inc. surged on Monday (Representative image: Getty Images)

Shares of AIM ImmunoTech Inc. (AIM) soared nearly 42% in Monday’s opening trade after the company announced that its pancreatic cancer trial hit a key enrollment milestone ahead of schedule.

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech

AstraZeneca PLC

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.1545
Prev Close	$0.161
Open	$0.164
Dividend Yield	0.00%
50-Day Moving Average	$0.1997
Beta	0.44
Avg. Volume	6.23M
PE Ratio	-0.04

52-Week High	$2.10
52-Week Low	$0.1503
Market Capitalization	$6.16M
EPS (Annual)	-$8.61
Price to Book	0.58
Revenue Per Employee	$4,631.58

Feed

News

Sentiment

Fundamentals

Info

AIM Fundamentals